Mereo BioPharma (MREO) Notes Payables (2017 - 2024)

Mereo BioPharma (MREO) has reported Notes Payables for 7 consecutive years, with $5.5 million the latest figure, recorded in Q4 2024.

• Quarterly Notes Payables changed N/A year-over-year to $5.5 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $5.5 million (changed N/A YoY) and the FY2024 annual result came in at $5.5 million, changed N/A from the prior year.
• Notes Payables held at $5.5 million in Q4 2024 per MREO's latest filing, from $5.6 million in the prior quarter.
• Over the last five years, Notes Payables for MREO reached as high as $16.5 million in Q2 2020 and fell as low as $4.6 million in Q1 2024.
• A 4-year average of $7.9 million and a median of $5.5 million in 2024 frame the typical range for Notes Payables.
• Annual changes were most pronounced in 2020 — Notes Payables surged 59.71% — and 2024, when it dropped 5.86%.
• Year by year, Notes Payables stood at $16.5 million in 2020, then fell by 21.0% to $13.0 million in 2022, then plunged by 59.71% to $5.2 million in 2023, then gained by 5.67% to $5.5 million in 2024.
• According to Business Quant data, Notes Payables over the past three periods registered $5.5 million, $5.6 million, and $4.9 million for Q4 2024, Q3 2024, and Q2 2024 respectively.